Your browser doesn't support javascript.
loading
Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
Blood Research ; : 55-57, 2013.
Article in English | WPRIM | ID: wpr-132573
ABSTRACT
Tacrolimus is a widely used immunosuppressive agent for the prophylaxis of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT). Since tacrolimus is primarily metabolized by the liver, hepatic dysfunction may affect its metabolism. Hepatic veno-occlusive disease (VOD) is an early complication of HSCT that results in hepatic dysfunction, suggesting that VOD may affect tacrolimus metabolism. We report a case of hepatic VOD accompanied by a sustained high blood trough level of tacrolimus despite its discontinuation. The findings of this case suggest that the elimination of tacrolimus can be markedly delayed in patients with hepatic VOD, and that the clinician should carefully modulate the drug dosage for these patients.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cells / Tacrolimus / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease / Liver Limits: Humans Language: English Journal: Blood Research Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cells / Tacrolimus / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease / Liver Limits: Humans Language: English Journal: Blood Research Year: 2013 Type: Article